Related Experiment Video
Updated: Dec 28, 2025
09:29
Studying Triple Negative Breast Cancer Using Orthotopic Breast Cancer Model
Published on: March 20, 2020
18.7K
Progress in triple negative breast carcinoma pathophysiology: Potential therapeutic targets
Kangjie Yu1, Joseph Rohr2, Yang Liu1
1State Key Laboratory of Tumor Biology, Department of Pathology, Xi Jing Hospital, the Fourth Military Medical University, Xi'an, Shaan Xi Province,710032, China.
Pathology, Research and Practice
|February 24, 2020
Summary
Triple-negative breast carcinoma (TNBC) is an aggressive cancer lacking effective treatments. This review explores emerging therapeutic targets and strategies for improving outcomes in TNBC patients.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- Triple-negative breast carcinoma (TNBC) is defined by the absence of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (Her2) expression.
- TNBC is characterized by high aggressiveness, poor prognosis, and limited targeted treatment options.
- There is a critical need for novel therapeutic strategies to improve survival rates in TNBC patients.
Purpose of the Study:
- To review and synthesize recent scientific evidence on novel therapeutic targets for TNBC.
- To summarize emerging and potential therapeutic regimens for treating TNBC.
- To identify promising avenues for future TNBC treatment development.
Main Methods:
- Comprehensive literature search of recent studies on TNBC.
- Analysis of preclinical and clinical data supporting novel therapeutic targets.
- Review of ongoing and proposed treatment strategies for TNBC.
Main Results:
- Identification of several promising molecular targets implicated in TNBC pathogenesis.
- Evaluation of novel therapeutic agents and drug combinations showing potential efficacy.
- Summary of evidence supporting the clinical translation of these findings.
Conclusions:
- Emerging research highlights several novel targets and therapeutic strategies for TNBC.
- Further investigation and clinical trials are warranted to validate these findings.
- These advancements offer hope for improved treatment outcomes in TNBC.
Related Concept Videos
02:57Targeted Cancer Therapies
8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
8.6K
02:07Tumor Progression
7.1K
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
7.1K
03:03mTOR Signaling and Cancer Progression
4.5K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
4.5K
02:38Mitogens and the Cell Cycle
7.6K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
7.6K
02:30Metastasis
6.3K
Metastasis is the spread of cancer cells from the original site to distant locations in the body. Cancer cells can spread via blood vessels (hematogenous) as well as lymph vessels in the body.
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
6.3K